Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BNT411 |
Synonyms | |
Therapy Description |
BNT411 is a TLR7 agonist, which activates B cells and CD8-positive T-lymphocytes as well as innate immune cells, potentially resulting in antitumor activity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BNT411 | BNT 411|BNT-411 | TLR7 Agonist 12 | BNT411 is a TLR7 agonist, which activates B cells and CD8-positive T-lymphocytes as well as innate immune cells, potentially resulting in antitumor activity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04101357 | Phase Ib/II | BNT411 Atezolizumab + BNT411 + Carboplatin + Etoposide | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | Terminated | USA | GBR | ESP | DEU | 0 |